AU Patent

AU2024203642B2 — Methods of treating Crohn's disease and ulcerative colitis

Assigned to AbbVie Inc · Expires 2025-08-21 · 1y expired

What this patent protects

#$%^&*AU2024203642B220250821.pdf##### ABSTRACT The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain e…

USPTO Abstract

#$%^&*AU2024203642B220250821.pdf##### ABSTRACT The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor. ABSTRACT The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor. 20 24 20 36 42 30 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 3 6 4 2 3 0 M a y 2 0 2 4 T h e p r e s e n t d i s c l o s u r e i s d i r e c t e d t o m e t h o d s f o r t r e a t i n g C r o h n ' s d i s e a s e , a n d i n p a r t i c u l a r , t o m e t h o d s f o r i n d u c i n g c l i n i c a l r e m i s s i o n a n d / o r e n d o s c o p i c i m p r o v e m e n t o f C r o h n ' s d i s e a s e , u s i n g a J A K 1 i n h i b i t o r . I n c e r t a i n e m b o d i m e n t s , t h e p a t i e n t i s a d m i n i s t e r e d a n i n d u c t i o n d o s e o f t h e J A K 1 i n h i b i t o r t o i n d u c e c l i n i c a l r e m i s s i o n a n d / o r e n d o s c o p i c i m p r o v e m e n t o f t h e C r o h n ' s d i s e a s e , f o l l o w e d b y a d m i n i s t r a t i o n o f a t l e a s t o n e m a i n t e n a n c e d o s e o f t h e J A K 1 i n h i b i t o r t h e r e a f t e r . I n o t h e r e m b o d i m e n t s , t h e p r e s e n t d i s c l o s u r e i s d i r e c t e d t o m e t h o d s f o r t r e a t i n g u l c e r a t i v e c o l i t i s u s i n g a J A K 1 i n h i b i t o r .

Drugs covered by this patent

Patent Metadata

Patent number
AU2024203642B2
Jurisdiction
AU
Classification
Expires
2025-08-21
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.